Bayer has reached a settlement with Plaintiffs in 500 more Yaz/Yasmin lawsuits. Bayer will pay an average of $220,000 per plaintiff to settle these claims. The total payout for these 500 cases will be $110 million.
I think Bayer has gotten rid of some of the smaller cases with this settlement. Not the gallbladder cases -which are going to be far lower if they settle at all – but I can’t imagine there are many heart attack and stroke cases, and certainly not any death cases where the patient did not have a boatload of other risk factors. Most of these Yaz settlements are going to be pulmonary embolism and deep vein thrombosis claims, where the final outcomes were quite good. (I suspect the pulmonary embolism cases settled for a good bit more than the deep vein thrombosis cases, too. The $220,000 is an average settlement.)
I think Bayer’s tactic here is twofold. First, they want to get a bunch of cases off their plate. The higher-ups in Germany are happy with less exposure. Second, I think they want to keep expectations down for the better Yaz/Yasmin lawsuits that are still out there. People are going to see this $220,000 average settlement number out of context and think that is what their claim is worth even though it may be a seven figure case.
There are going to be a lot more Yaz lawsuits and bigger settlements before this is over. If you are a woman who suffered a blood clot, pulmonary embolism, heart attack or stroke, and have been waiting to see how these Yaz settlements play out, time might be running out. You don’t want to miss out on the opportunity to get in on these group settlements and you have to be concerned as to whether your claim will be barred by the statute of limitations.